glp 1 approved for cardiovascular disease A new Science Perspective highlights the growing body of evidence that hints at the potential of GLP-1–based medications in treating conditions other than diabetes and obesity, including and neurodegenerative disorders Emulated Effects of Glucagon-Like Peptide

BPC-157, an experimental compound, is believed to exert its effects through multiple mechanisms, including promoting blood vessel formation (angiogenesis), enhancing tissue regeneration, and modulating various growth elements and signaling pathways involved in tissue repair

More specifically, receptors levels in the frontal and temporal cortex were reduced by approximately 50% of control values in AD patients while a 40% reduction was reported in the hippocampus and no significant changes were found in the cingulate cortex, postcentral gyrus, temporal pole, and superior temporal gyrus

However, more frequent testing at 3 to 6 months may be needed if you experience significant weight loss, as this can alter thyroid hormone requirements

The author is not disseminating any information, which the author believes or knows, is confidential or in conflict with the privacy of any person

Neuropsychopharmacology (2001) 25:62432

If you experience any side effects, whether listed above or in the patient information leaflet, please inform your doctor